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Introduction
Lung cancer is a significant cause of morbidity and the 
leading cause of cancer mortality in Australia [1]. In 2016, 
lung Cancer accounted for about 9% all new cancers diag-
nosed and 18% of all cancer deaths in Australia [1]. Limited 
data exists detailing how lung cancer patients flow through 
the healthcare system, and the delays and barriers that may 
interfere with the patient journey. The availability of evi-
dence-based guidelines and multidisciplinary meetings has 
improved clinical effectiveness but does not automatically 
translate into improved quality of care [2]. Various studies 
done in Australia and other countries have revealed delays 
in lung cancer diagnosis and treatment, especially for rural 
patients [3–7]. The limited access to cancer care services is 
a significant issue faced by residents of rural, remote and 
regional communities [8–10].
Cancer patients utilise a wide range of services from mul-
tiple providers at various points during their cancer journey, 
including oncologists, primary care physicians, nurses, phar-
macists, physiotherapists and social workers [6]. They fre-
quently experience fragmented health care journeys and 
suffer from lack of continuity of care [11]. Given the high 
cost and complexity of their evolving needs from the point 
of diagnosis to either survivorship or palliative care, cancer 
patients require care that is integrated across providers and 
settings over time [12, 13]. Implementation of a ‘Cancer Care 
Pathway’ might be a way of improving patients’ care experi-
ences and to improve the efficiency of the health  system [14].
Optimal care pathways are structured, multidiscipli-
nary care plans for a specific clinical condition, which 
describe the tasks to be pursued, their timing, sequence 
and the professionals involved [15, 16]. Implementation 
of optimal care pathways has been shown improve the 
outcomes of cancer patients, improve patient satisfaction 
and reduce costs [17]. Although the elements and frame-
works are similar for many cancer-related pathways, each 
type of cancer requires specific approaches in terms of 
investigations and management modalities and applica-
tions; thus, requiring adaptations of pathways to both the 
kind of cancer and to local needs and settings [18]. Various 
international oncology societies have published criteria 
for the development and implementation of oncology 
pathway programs within their jurisdictions as listed in 
Table 1 [20, 25–28, 56]. Cancer Australia has published 
optimal care pathways for common cancers, including 
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lung cancer, to guide the delivery of consistent, safe and 
high-quality care for cancer patients in Australia [20].
However, there is currently only limited consensus 
around the definition of the optimal care pathway, and 
there are various terminologies used interchangeably in 
the literature [19, 21]. Little is known about how integrated 
care plans for cancer patients are developed, including the 
definition of core activities, the specifications for facili-
tators and the determination of indicators for assessing 
impact [22]. There is also only limited data to guide the 
implementation of optimal care pathways for lung cancer 
patients in the cancer centre environment. While major 
metropolitan cancer centres have the capacity to access all 
components of the optimal care pathway, including access 
to clinical trials, many regional centres may not have 
access to various components of the pathway [15]. This 
may mean that the patients may not receive the recom-
mended investigations and care [23]. Due to the large geo-
graphical catchment area and the greater travel distances 
for patients, our regional cancer centre has embarked on 
developing cancer care pathways suitable for our region.
As part of developing our own lung cancer pathway to 
cater for our population, this review aims to identify and 
summarise the available literature on lung cancer path-
ways. A scoping review was conducted in order to explore 
the key components of lung cancer care pathways, iden-
tify the facilitators and barriers associated with their use 
and to examine the outcome measures that have been 
determined to assess their impact.
Methodology
This review of the literature used the scoping review meth-
odology as defined by Arksey and O’Malley [24]. Scoping 
reviews are commonly used to understand the existing 
breadth of research on a topic, identify gaps in the exist-
ing literature and assess the need for further research [24]. 
Arksey and O’Malley described five stages of methodologi-
cal framework for a scoping review.
Our research question was refined to: ‘What is known 
from the existing literature about the implementation 
and evaluation of optimal care pathways for people with 
lung cancer?’
Identifying relevant studies
Published articles were identified from electronic litera-
ture databases including MEDLINE, PubMed, Embase, and 
Google Scholar. Hand searching of reference lists and grey 
literature, including Cancer Institute publications, govern-
ment websites, websites of cancer societies and cancer 
foundations was also done. The literature search was done 
using key search terms; (‘optimal care pathways’ or ‘inte-
grated care pathways’ or ’critical pathways’ or ‘clinical care 
pathways, protocol’) AND (‘lung cancer’ or ‘lung neoplasm’). 
Only articles in the English language were selected.
Two authors (ZO and AB) independently reviewed and 
screened the abstracts for selection, using the following 
inclusion criteria:
Articles were included if,
•	 The optimal care pathway was being used to manage 
adult patients with lung cancer.
•	 The article reported on either the development pro-
cess and outcomes and/or barriers and facilitators 
associated with optimal care pathway development 
and/or uptake.
Articles were excluded if:
•	 The optimal care pathway was used for management 
of cancers other than lung cancer.
•	 The articles were concerned with only screening and 
prevention of lung cancer.
•	 The articles purely focusing on treatment algorithms 
of specific sub-specialities.
Study selection
The process of selection of articles for the final review is 
depicted in Figure 1.
Reasons for excluding full text articles included the fol-
lowing: articles dealing only with post-operative care (six), 
studies looking at systemic therapy in lung cancer (five), 
articles that included other types of cancers apart from 
lung cancer (four), articles dealing with molecular path-
ways (four) and articles that consisted of systematic review 
(three).
Categorisation of studies into themes
Two authors (ZO, SS) independently reviewed the results 
and categorized the studies into sub-themes. Final themes 
were developed through consensus between authors and 
as follows:
•	 Development and implementation of lung cancer 
pathways
Table 1: Examples of optimal lung cancer pathways.
Group Pathway Year
Cancer Council, Australia [20] Optimal cancer care pathways for people with Lung Cancer. 2016
Cancer Care Ontario, Canada [25] Lung Cancer Pathway Map 2019
Swedish Lung Cancer Study Group, Sweden [26] Recommendations from the Swedish Lung Cancer Study Group 1999
Lung Clinical Expert Group, UK [27] National Optimal Lung Cancer Care Pathway implementation guide 2017
UK Lung Cancer Coalition, UK [28] Implementing National Optimal Lung Cancer Pathway 2018
National Health Service (England) [57] Implementing a timed Lung Cancer Diagnostic Pathway 2018
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•	 Use of quality indicators to audit lung cancer care 
pathways
•	 Studies on outcomes of lung cancer pathways:
 ◦ Improved timeliness of care delivery
 ◦ Studies on patient experiences
 ◦ Studies on health care utilisation and costs
Charting the data
Data are summarised under each category in Table 2 
(supplementary material).
Results
A total of 421 references were retrieved and from these, 
32 articles were selected for the final review. Out of these, 
six were guidelines published by professional organisations 
on implementing optimal care pathways for lung cancer, 
in their respective countries (Table 1). Eight of the articles 
dealt with development and implementation of optimal 
lung cancer care pathways. Five studies were on auditing 
lung cancer care pathways using quality indicators, four 
on evaluating the patients’ experience of lung cancer care 
pathways, five studies were on timeliness of care using lung 
cancer care pathways and four studies on health care utili-
sation and costs associated with lung cancer care pathways.
The care pathways vary significantly in their formats 
and implementations, depending upon the health system. 
Articles originated from a range of countries including 
both public and private health systems. Out of 32 articles, 
thirteen were from the United Kingdom, four were from 
the United States, four from Canada, three from Australia, 
four from Italy, and the remainder from other countries.
Various government organisations and professional 
bodies have published guidelines for implementation 
of optimal lung cancer pathways [20, 25–28]. Although 
there are variations in the recommended investigations 
and timeframes, all the guidelines aim to provide timely 
and effective care for people with suspected lung cancer. 
These pathways chart the optimal journey of a person 
with suspected lung cancer from diagnosis to treatment 
and follow up. They also contain information on lung can-
cer prevention, supportive care and palliative care. A wide 
range of clinicians, peak health organisations, consumers 
and carers were consulted and participated in their devel-
opment [20].
Development and implementation of lung cancer care 
pathways
Eight studies focused mainly on the processes and chal-
lenges of implementing lung cancer care pathways. The 
implementation of lung cancer pathways was made in 
multiple steps, involving multi-disciplinary teams within 
the oncology community. One of the first steps in imple-
menting a lung cancer pathway is ‘process mapping’, in 
which the existing lung cancer pathway in the region is 
mapped and weak points identified [28]. Streamlining 
administration and use of the best information technol-
ogy tools are also an important part of implementing the 
pathway [29].
Most of the care pathways were designed by multidis-
ciplinary teams, consisting of clinicians who are directly 
involved in lung cancer management and health care 
researchers [24, 30–36]. Patient involvement in the design 
Figure 1: Flow chart for selection of articles.
Records Identified through 
database search (n=96) 
Records Identified through selective search 
of journals, reference lists and grey 
literature (n= 325) 
Records after duplicates 
removed (n = 381)
Abstracts of records 
screened (381) 
Full-text articles assessed 
for eligibility (n =54) 
Studies included in the 
review (n =32) 
Records excluded 
(n =327) 
Full-text articles excluded 
 (n =22) 
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of care pathways was quite limited, with only a few studies 
reporting patient engagement [36, 37]. The care pathways 
needed to be revised over time, and there were specific 
teams who were tasked with monitoring the uptake of the 
pathway [30, 32, 38–40]. The care pathways were often 
linked to patients’ electronic medical records [30, 40, 41]. 
By using computer-based platforms, aggregating data on 
treatment decisions and care delivery were facilitated [40]. 
There was a strong emphasis placed upon sharing infor-
mation between teams and across organisations in most 
care pathways [31, 39–41].
In the ‘Cancer Care Ontario Lung Cancer Disease 
Pathway’, diagnostic and treatment pathways for lung 
cancer were posted on a website [32]. Representatives 
from primary care, public health, occupational medicine, 
oncology, patients and their care givers participated in 
formulating this pathway [32]. Some centres addressed 
the delays in lung cancer care by redesigning the regional 
model of care [29]. The Ottawa Hospital Model operation-
alised the lung cancer diagnostic pathway and optimised 
patient flow from referral to initiation of treatment. All 
the stakeholders including health care professionals, 
patients, caregivers and administrators, participated in re-
designing the lung pathway [29]. Lung cancer care path-
ways can be implemented in a regional setting, where the 
GPs have access to same-day chest X-ray and CT scan and 
adequate staffing of daily lung cancer clinics [42]. A lung 
cancer patient navigator coordinated patient referrals 
from a large rural catchment area [42].
Various modifications to the lung cancer care pathways 
have reduced delays to diagnosis and improved the effi-
cacy of the pathways, including employment of a lung 
cancer nurse specialist [43, 44], straight-to CT pathway 
[44] and immediate reporting of chest x-rays by a radiog-
rapher [45]. Quick turnaround time for pathology report-
ing is essential for implementing an optimal lung cancer 
pathway, and delays in pathology reporting can be due 
to logistical issues or requests for molecular testing [46]. 
Qualitative studies on local lung cancer care pathways in 
the National Health Service, England, showed that the 
strengths of the services included leadership, good team 
work, good relationships within the service, ownership, 
and quick turnaround times for some of the tests [47].
The challenges included radiology and oncology capac-
ity, insufficient clinical information from GPs and lack 
of consistency and delay in Multi-Disciplinary Treatment 
decisions [47]. One-Stop Clinics, where the patients are 
seen by multiple specialists on the same day and multiple 
investigations are organised have also been successfully 
trialled [47].
Using quality indicators to audit lung cancer care 
pathways
There were five studies on quality indicators and auditing 
lung cancer pathways [33, 37, 38, 48, 49]. The group from 
the University of Udine in Italy selected quality indicators 
from international guidelines and after discussions with 
the local multidisciplinary thoracic malignancy group 
[33]. These quality indicators can be used to identify 
problems in the local lung cancer pathway, such as delays 
and non-adherence to clinical guidelines [38]. Investiga-
tors from the University of Sheffield interviewed profes-
sionals from primary, secondary, tertiary and palliative 
care, and developed paper-based forms to monitor the 
progress of lung cancer patients and audit the key stand-
ards within the pathway [37]. Quality indicators can also 
be used to verify adherence to clinical practice guidelines 
and elicit some critical issues in the care of lung cancer 
patients [48]. The results from auditing studies need to 
be shared with hospital managers, with the aim of rede-
signing lung cancer care pathways and improving the 
efficiency of care [48].
Outcomes of lung cancer care pathways
1. Improved timeliness of care
Optimal lung cancer care pathways aim to reduce the time 
delays experienced by patients in seeing a specialist to do 
specific investigations and to start treatment [24, 36]. 
 Several studies have described the processes that were 
implemented in the respective hospitals to reduce the 
time to diagnosis and treatment [30, 35, 44, 51, 52]. This 
was done using novel management systems [30], and by 
the provision of adequate resources and improved com-
munication between departments [35]. Quality improve-
ment instruments like the ‘Lean Model’ programme was 
successfully utilised in order to reduce the delays in the 
lung cancer pathway and to improve patient flow [30]. 
Information technology-driven optimal care pathways 
and virtual clinics shortened diagnostic timeframes, 
even in regional hospitals [52]. One of the methods used 
to reduce delays in diagnosis of lung cancer is to auto-
matically trigger a referral for CT scan if the chest x-ray is 
abnormal [44].
2. Effect on health care utilisation and costs
Standardised clinical care pathways for the investigation of 
patients with lung cancer allow for a reduction in the time 
interval between suspicion of lung cancer and treatment, 
lower costs and increase patient satisfaction and quality of 
care [52]. Treatment pathways mainly deal with the best 
systemic treatment options for a lung cancer patient at a 
certain point of care. Systemic therapy was selected based 
on its efficacy, toxicity profile and cost-effectiveness [31, 
39, 40]. Pathways reduced the cost of lung cancer treat-
ment without compromising survival [39, 40].
3. Studies on patient experience
One of the aims of implementing an optimal lung cancer 
care pathway is to improve patients’ experiences and sat-
isfaction with their care [20]. Perspectives of lung cancer 
patients, evaluated using the OPTION (Opportunity for 
Treatment in Oncology) questionnaire, give the highest 
scores to ‘respect’, ‘satisfaction’, and ‘trust’ [53]. Offering 
written communication about diagnosis and maintaining 
patient privacy during consultations improves patient sat-
isfaction [54]. Hagglund et al. (2015) from the Karolinska 
institute in Sweden, studied patients’ experiences of living 
with lung cancer and created a ‘patient journey model’ 
[34]. The problems experienced by patients in each phase 
were identified and eHealth solutions for these problems 
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were proposed [34]. Investigators from the University of 
Memphis compared patients’ perspectives of multidisci-
plinary lung cancer care to routine serial care [36]. They 
found that participants preferred multiple physicians 
working together as a team to decide on the best plan of 
care.
Barriers to implementation of optimal lung cancer 
care pathways
Barriers to implementing lung cancer care pathways can 
occur at various levels. Some of the common challenges 
include resource limitation, diagnostic and treatment 
capacity and complex patients [47, 55]. Some hospitals 
will not have specialist investigations like PET scans or 
endobronchial ultrasounds and have to refer patients to 
other centres, thereby delaying the diagnosis and staging 
of lung cancer [55]. There will be limitations to the num-
ber of CT scans or biopsies that can be done in a day. Fol-
lowing the initiation of a new lung cancer pathway, there 
may be an increased number of primary care requests for 
CT scans [47]. Collaborative working and good communi-
cation between various departments can overcome these 
issues [28]. Clinicians can be reluctant to use new forms or 
pathways [30, 37]. Two common barriers to implementing 
the pathway in the cancer care Ontario study were slow 
referral processes and lack of administrative support [32]. 
Members of the lung cancer pathway team would have 
concerns about over burden and increased workload [28]. 
Part-time GPs and lack of ability to review X-ray and CT 
reports on a daily basis can pose a challenge [28]. Local 
lung cancer pathway data has to be validated for quality 
control, but this could be a challenge [28]. Some of the 
health services would have difficulty in funding the opti-
mal lung cancer pathway implementation [56, 57].
Discussion
Optimal cancer care pathways map the cancer patient’s 
journey for specific tumour types in order to promote 
quality cancer care and improve the patient’s experi-
ences. The optimal care pathway for lung cancer has 
been endorsed by health authorities in Australia and its 
key features include the following: patient-centred care, 
safe and quality care, multidisciplinary care, and improved 
coordination and communication [20]. This pathway out-
lines seven critical steps in a lung cancer patient’s journey 
which are prevention, initial investigations and referral, 
diagnosis and treatment planning, treatment, follow up 
after treatment completion, management of recurrent 
cancer and end-of-life care [20]. Similar lung cancer care 
pathways have been developed in other countries [25–
28]. Previous reviews on optimal lung cancer care path-
ways were focused on timeliness of care [56, 58] or barri-
ers to early diagnosis [59]. There are no overviews of the 
whole lung cancer care pathway from prevention to end 
of life care. In addition, components of the pathways are 
likely to be context specific based on many factors includ-
ing resources. Therefore, a one size fit all approach is not 
applicable in this setting and contents need to be adapted 
for local needs and based on resources. One of the aims of 
this scoping review is to identify existing successful exam-
ples and innovations in the literature so that centres want-
ing to establish local lung cancer pathways can leverage 
existing experience.
The type and scope of lung cancer pathways in this 
review varied significantly. The studies included in this 
review were either related to implementing national opti-
mal cancer care pathways in their institution or audit-
ing the quality of the optimal care pathway. Some lung 
cancer pathways were employed in single hospitals while 
others were employed on a much wider scale; focusing 
exclusively on the clinical elements of care or have tar-
geted individual stages in the cancer trajectory, rather 
than considering integrated care along the continuum 
[11, 12].
Implementation of lung cancer care pathways had 
positive impacts on patient care in most of the studies. It 
has shown to reduce waiting times for diagnosis and treat-
ment [30, 35, 44, 50, 51]. This appears to be associated 
with better patient outcomes and higher patient satisfac-
tion [34, 36, 52–54]. The cost of cancer therapies is a sig-
nificant issue, and it has been rising with the introduction 
of new (and often more expensive) therapies [13]. Studies 
looking at the cost effectiveness of lung cancer pathways 
demonstrated reduced costs [39, 40, 52]. Cost savings 
were made either by selecting cheaper, but appropriate 
chemotherapy agents [39, 40] or by reducing delays and 
avoiding unnecessary investigation [52].
This review has identified some strategies for imple-
mentation of various steps of lung cancer care pathways. 
Initial steps include engagement of multidisciplinary 
professionals and ‘process mapping’. Process mapping 
identifies components of existing systems and areas of 
deficiencies [22]. The engagement and involvement of 
clinical providers helps foster a sense of ownership [2, 23, 
24]. Development and implementation of the lung cancer 
pathway should be driven by clinicians, health scientists 
and consumers [31] although most of the studies in this 
review did not have formal mechanisms for involving con-
sumers in design.
Some examples of structural factors that enable imple-
mentation include a dedicated team of professionals to 
oversee the implementation and operationalisation of 
the care pathway and undertake quality improvement 
activities. [4, 24]. Many centres employed dedicated 
lung cancer care nurses or nurse navigators or dedicated 
physicians to coordinate and spearhead their lung can-
cer services [42, 43]. Cultural factors include leadership, 
teamwork, and good relationships within the service as 
exemplified by the ACE Lung Cancer Pathway cluster in 
United Kingdom [47].
Our review also identified some innovations and exam-
ples that were used to streamline and expedite the patient 
journey at the diagnosis stage of the pathway. These 
include the following: access by GPs to same day CXR 
and CT scans (42), straight-to CT pathway (44), automatic 
referral for CTs when an abnormality was found on CXRs 
(44), and immediate reporting of CXR by radiographers. 
In terms of management and multidisciplinary stage, 
One-Stop Clinics, where the patients are seen by multiple 
specialists on the same day and multiple investigations 
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are organised have also been successfully trialled [25]. 
However, this may not be feasible at smaller regional or 
rural centres due to workforce and space issues.
In terms of patient information management, elec-
tronic and web-based platforms seem to be more widely 
used to implement lung cancer pathways [5, 23, 24, 26]. 
With the widespread use of smartphones and tablets, 
these pathways may be accessible to most specialist and 
primary care providers and patients. Information tech-
nology-driven optimal care pathways and virtual clinics 
shortened diagnostic timeframes even in regional hospi-
tals [14]. Electronic systems offer other advantages includ-
ing ease of remote access, data sharing by MDT members 
and use of quality indicators to monitor and improve the 
Pathway [60].
Some of the studies in this review have utilized quality 
indicators that were used by other centres for research on 
lung cancer pathways [4, 27–29]. These quality indicators 
can be used to identify problems in the local lung can-
cer pathway, such as delays and non-adherence to clini-
cal guidelines [4]. A good practice is to share these data 
with managers with the aim of improving lung cancer 
care pathways and the efficiency of health care delivery 
[29]. The pathway tools will not achieve maximum success 
without an actual engagement of the hospital manage-
ment [33]. Even after the cancer care pathway is imple-
mented, it must be audited periodically, in order to ensure 
that all aspects of pathway are running optimally [38, 49]. 
This requires a dedicated team of professionals, who can 
periodically allocate time to hold meetings and monitor 
the performance of the care pathways, and continuously 
adjust and improve their content [38].
Despite investment by governments on lung cancer 
pathways, clinicians, patients and system managers face 
many barriers to implementing the lung cancer path-
ways. Some example of barriers include the following: 
inadequate support from clinicians because of concerns 
of increased-workload (28), limited integration between 
primary care and tertiary care (47), slow referral processes, 
limited resources and administrative support, lack of 
training for providers regarding the pathway and inad-
equate information technology support (32). While larger 
teaching hospitals have put significant resources into fast 
tracking diagnosis, diagnostic and staging technologies 
and molecular genotyping of lung cancer [6], this may not 
be possible in the community setting and smaller centres 
due to limitations of resource, workforce and leadership 
capabilities.
Our review has some limitations. To manage scope, we 
excluded studies examining the pathways in other cancers 
that might have solutions applicable to lung cancer. We 
identified only a few studies on implementing care path-
ways in predominantly rural populations that face many 
of workforce and resource related barriers [4]. However, 
rural centres wishing to set up lung cancer pathways could 
take advantage of telehealth technologies to connect to 
larger centres and acquire workforce capabilities remotely. 
In addition, these centres could leverage consumers and 
the data on inequity of access and disparity in outcomes 
to lobby for additional resources to set up care pathways.
Conclusion
The limited number of relevant articles found in this 
review may suggest that an optimal care pathway for 
lung cancer is still in its preliminary stages across the 
broader health systems. Clinical leadership, involvement 
of multidisciplinary clinicians and managers, dedicated 
administration or nursing support, innovative solutions, 
integration of pathways into user-friendly IT platform, and 
quality improvement mechanisms seem to be important 
components for successful implementation of a lung can-
cer care pathway. Smaller centres could take advantage of 
telehealth technologies to connect to larger centres and 
acquire workforce capabilities remotely. Depending on 
the geographical location and resource constraints, the 
optimal lung cancer pathway needs to be adapted for 
local setting with inclusion of innovations to overcome 
deficiencies. Since different health services have different 
types of referral patterns for lung cancer, local workflow 
issues must be considered and problems with the lung 
cancer pathways need to be solved at the local health ser-
vice level.
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